Please login to the form below

Not currently logged in
Email:
Password:

American Heart Association meeting

This page shows the latest American Heart Association meeting news and features for those working in and with pharma, biotech and healthcare.

Amgen's Repatha unclogs blocked arteries, says study

Amgen's Repatha unclogs blocked arteries, says study

At the American Heart Association (AHA) annual meeting this week, lead study author Stephen Nichols of the University of Adelaide in Australia reported that adding a monthly Repatha shot to daily ... The results have also been published in the Journal of

Latest news

  • Sanofi plans 18 new product launches by 2020 Sanofi plans 18 new product launches by 2020

    These include cholesterol-lowering antibody alirocumab (now given the proposed trade name of Praluent) - fresh from encouraging new data presented at the American Heart Association meeting - as well a vaccine against ... the company will be keen to

  • PCSK9 inhibitor alirocumab works in statin-intolerance PCSK9 inhibitor alirocumab works in statin-intolerance

    PCSK9 inhibitor alirocumab works in statin-intolerance. Sanofi and Regeneron’ s drug impresses at American Heart Association meeting. ... The ODYSSEY ALTERNATIVE trial - reported at the American Heart Association (AHA) meeting in Chicago this week -

  • Merck's ezetimibe has 'modest' benefit when added to statins Merck's ezetimibe has 'modest' benefit when added to statins

    Results presented at the American Heart Association (AHA) meeting showed that 32.7% of Vytorin-treated patients suffered a major cardiovascular event over a median seven-year follow-up period, compared

  • US FDA deems Novartis' heart failure candidate a 'breakthrough' US FDA deems Novartis' heart failure candidate a 'breakthrough'

    US FDA deems Novartis' heart failure candidate a 'breakthrough'. Serelaxin demonstrates ability to reduce shortness of breath and lower chance of dying. ... It also seems to boost kidney function and cardiac output. The RELAX-AHF data was first unveiled

  • Novartis' heart failure drug serelaxin meets targets Novartis' heart failure drug serelaxin meets targets

    Top-line data from the RELAX-AHF study were reported in September, but more detailed and updated results have been presented this week at the American Heart Association (AHA) annual meeting ... all-cause and cardiovascular mortality whilst appearing to

More from news
Approximately 1 fully matching, plus 11 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Atlantis Healthcare

Atlantis Healthcare is a global leader in optimising patient self-management. Established in 1996, we design, develop and implement scalable solutions...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics